Page 1 of 4

The benefit-risk ratio of Rosiglitazone therapy is not defined

Diabetes is a strong, independent risk factor for cardiovascular disease, a problem which accounts for approximately 70% of all mortality in people with diabetes. Prospective studies show that compared to their non-diabetic counterparts, the relative risk of cardiovascular mortality for men with d...
Read Article

Saxagliptin added to Metformin improves glycemic control in patients with type 2 diabetes compared to Metformin alone

Phase III data demonstrated that Saxagliptin, an inhibitor of dipeptidyl-peptidase-4 ( DPP-4 ), in combination with Metformin, exhibited a statistically significant improvement in glycemic control in subjects with type 2 diabetes compared to Metformin alone through 24 weeks of treatment. A group ...
Read Article

Sertraline may prevent recurring depression in diabetics

The antidepressant Sertraline ( Zoloft ) may reduce the risk of recurrent depression and increase the period of time between episodes of depression in patients with diabetes. One of every four patients with diabetes experiences clinical depression. Among those with diabetes, depression can reduc...
Read Article

Exubera: no evidence available of an additional therapeutic benefit

IQWiG, The German Institute for Quality and Efficiency in Health Care, has published a comparative review of inhaled Insulin ( Exubera ) versus Insulin administered subcutaneously. There is currently no evidence available that Exubera in diabetes therapy shows advantages over short-acting human I...
Read Article

Exenatide reduces blood glucose levels when added to patients using a thiazolidinedione

A study showed that Exenatide ( Byetta ) injection lowered blood glucose levels for people with type 2 diabetes who had not achieved target blood glucose levels despite the use of a thiazolidinedione with or without Metformin. Patients using Exenatide showed improvements in three important measu...
Read Article

Exubera's long-term efficacy and safety in adults with type 1 or type 2 diabetes

Results from two ongoing studies showed adults with type 1 or type 2 diabetes treated with Exubera, a rapid-acting, dry powder human Insulin, experienced sustained blood glucose control over a two-year period and gained about half as much weight as those taking injected Insulin. Type 2 diabetes...
Read Article

Peripheral neuropathic pain: Lyrica is not recommended for use within NHS Scotland

The Scottish Medicines Consortium ( SMC ) has advised NHS ( National Health Service ) Boards and Area Drug and Therapeutic Committees ( ADTCs ) that Pregabalin ( Lyrica ) is not recommended for use within NHS Scotland for the treatment of peripheral neuropathic pain in adults. Comparative clinica...
Read Article

Children with type 1 diabetes: physical activity linked to improved glucose control

A study, published in the Archives of Pediatrics & Adolescent Medicine, found that children with type 1 diabetes who exercise regularly may have improved blood glucose levels compared with those who do not, and regular physical activity does not appear to increase the risk of severe hypoglycemia. ...
Read Article

Combination of Vildagliptin and Pioglitazone in patients with type 2 diabetes

Vildagliptin ( Galvus ), a new once-daily oral treatment option for type 2 diabetes, has demonstrated efficacy, especially in patients with poor glycemic control, as well as weight loss benefits in obese patients. Vildagliptin, a member of the DPP-4 inhibitor class, works through a novel mechanis...
Read Article

Exenatide: sustained improvements in blood glucose control and progressive weight loss after two years

A two-year study has shown that Exenatide ( Byetta ) injection sustained improvements in blood glucose control and reduced body weight in people with type 2 diabetes who previously did not achieve adequate control of their blood sugar on common oral medications. After two years of treatment, pati...
Read Article